Annexon Price Target Raised to $15.00/Share From $14.00 by JP Morgan
JP Morgan has increased its price target for Annexon from $14.00 to $15.00 per share. This adjustment indicates a positive outlook from the financial institution regarding Annexon's future stock performance.
JPMorgan raises Annexon Biosciences price target on trial data By Investing.com
JPMorgan increased its price target for Annexon Biosciences (NASDAQ:ANNX) to $15.00 from $14.00, maintaining an Overweight rating, based on the anticipated Phase 3 ARCHER II study results for vonaprument. The stock is currently trading at $4.08, implying a potential 267% upside, with key 15-month trial data expected in Q4 2026. Despite a year-to-date decline, the stock has gained 35% over the past year and InvestingPro analysis suggests it is slightly undervalued, holding more cash than debt, though it is burning through cash.
Insider Spends US$100k Buying More Shares In Annexon
Annexon's CEO, President & Director, Douglas Love, recently purchased US$100k worth of company stock. While this individual purchase signals confidence, the overall insider transaction history for the past year shows more selling than buying. Insiders collectively own 0.9% of Annexon shares, valued at US$6.2 million.
Annexon (ANNX) President and CEO Douglas Love Buys 26,065 Shares
Douglas Love, President and CEO of Annexon Inc (ANNX), recently purchased 26,065 shares of the company on September 24, 2026, increasing his total holdings to 390,476 shares. The transaction, valued at $3.83 per share, signals confidence from the executive in the clinical-stage biopharmaceutical company, which focuses on developing treatments for autoimmune, neurodegenerative, and ophthalmic diseases. This insider buy contributes to a slightly positive insider activity trend for Annexon over the past year, with 12 buys versus 10 sells.
After buying shares at a $3.83 average, Annexon (ANNX) CEO Love Douglas holds 390,476 shares.
Annexon, Inc. President and CEO Love Douglas purchased 26,065 shares of common stock on September 24, 2026, at a weighted average price of $3.83 per share, bringing his direct holdings to 390,476 shares. The transaction, executed in multiple trades ranging from $3.815 to $3.829, was reported as a neutral filing with positive sentiment.
More than 8 million people have an eye disease that can cause blindness. Annexon will present trial findings.
Annexon (ANNX) will present data from its vonaprument Phase 3 ARCHER II trial and a post hoc analysis of Phase 2 vision outcomes at The Retina Society's annual meeting on September 25, 2026. The presentations will cover baseline characteristics of participants in the ARCHER II trial for geographic atrophy (GA), a leading cause of blindness, and highlight findings from the Phase 2 ARCHER study. Month 15 results for the ARCHER II trial are expected in Q4 2026, with vonaprument designed as a potential first-in-kind vision-protecting therapy for GA.
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
Annexon, Inc. announced two oral presentations at The Retina Society 59th Annual Scientific Meeting regarding vonaprument for geographic atrophy (GA). The presentations will highlight patient baseline characteristics from the Phase 3 ARCHER II trial and vision outcomes from the Phase 2 ARCHER trial, aiming to demonstrate vonaprument's potential to protect vision in GA patients. Results from the ARCHER II trial are anticipated in the fourth quarter of 2026.
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. announced inducement grants to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved in accordance with Nasdaq Listing Rule 5635(c)(4). These grants include options to purchase 275,500 shares of Annexon common stock at an exercise price of $3.92 per share, vesting over four years. The biopharmaceutical company focuses on advancing immunotherapies for neuroinflammatory diseases.
Annexon at Cantor Fitzgerald conference: eye data, gbs progress By Investing.com
Annexon presented at the Cantor Fitzgerald Global Healthcare Conference, highlighting positive clinical data for its two late-stage neuroinflammatory disease programs. The company's lead eye drug, vonaprument, showed significant vision preservation in geographic atrophy, with an enrollment ahead of schedule for its Phase III ARCHER II study. Additionally, Annexon reported a 100% response rate in open-label data for its Guillain-Barré syndrome program, with regulatory filings underway in Europe and planned for the FDA.
Annexon to Participate in Upcoming September Investor Conferences
Annexon, Inc. (Nasdaq: ANNX) announced that its President & CEO, Douglas Love, will participate in three upcoming investor conferences in September 2026: the Wells Fargo 21st Annual Healthcare Conference, the Cantor Global Healthcare Conference, and the H.C. Wainwright 28th Annual Global Investment Conference. Live webcasts of these presentations will be available on Annexon's website, with replays archived for 30 days. The company focuses on developing targeted immunotherapies for neuroinflammatory diseases.
Annexon to Participate in Upcoming September Investor Conferences
Annexon, Inc. (Nasdaq: ANNX) announced that its President & CEO, Douglas Love, will participate in three upcoming investor conferences in September 2026. These include the Wells Fargo 21st Annual Healthcare Conference, the Cantor Global Healthcare Conference, and the H.C. Wainwright 28th Annual Global Investment Conference. Live webcasts and replays will be available on Annexon's investor relations website.
ANNEXON, INC. : JP MORGAN RAISES TARGET PRICE TO $14 FROM $10
JP Morgan has increased its target price for ANNEXON, INC. shares from $10 to $14. This revision suggests an improved outlook from the financial institution regarding the company's future stock performance.
Annexon Biosciences Bets Big on Pivotal Trial Wins
Annexon Biosciences presented an optimistic outlook during its Q2 earnings call, highlighting significant clinical progress with tanruprubart for Guillain-Barré syndrome (GBS) and disciplined execution in geographic atrophy (GA) trials. The company also secured a non-dilutive credit facility, extending its cash runway into 2028. While acknowledging statistical complexities and debt obligations, Annexon remains confident in its pipeline and regulatory timelines, anticipating a period rich in catalysts.
Annexon, Inc. (ANNX) Free Cash Flow 2025: $186.5M outflow, down 58.0%
Annexon, Inc. (ANNX) reported a free cash flow outflow of $186.5 million in fiscal year 2025, marking a 58.0% decrease from the previous year. Over the trailing 12 months (Q3 FY2025 through Q2 FY2026), the company recorded a free cash flow outflow of $193.2 million. This article provides a detailed breakdown of ANNX's annual and quarterly free cash flow figures from 2019 to 2026, alongside explanations of what free cash flow represents.
Annexon, Inc. (ANNX) Net Income 2025: $206.7M net loss, down 49.6%
Annexon, Inc. (ANNX) reported a net loss of $206.7 million in fiscal year 2025, marking a 49.6% decrease from the previous fiscal year. Over the past seven fiscal years, the company's net income has trended from a loss of -$37.2 million in 2019 to -$206.7 million in 2025. In the most recent quarter (Q2 2026), ANNX recorded a net loss of -$55.3 million, a 12.6% decrease year-over-year.
Annexon (ANNX) Institutional Ownership 2026
This article details the institutional ownership of Annexon (ANNX) as of 2026, providing data on institutional buyers and sellers, total inflows and outflows, and a list of major shareholders with their respective holdings and market values. It highlights that 105 institutional buyers invested $315.19M in the last 12 months, while 30 institutional sellers divested $18.85M. Key shareholders include Palo Alto Investors LP, Redmile Group LLC, and BlackRock Inc.
Annexon, Inc. Stock 12‑Month Price Target Raised to $15.71, Implies 198% Upside
Annexon, Inc.'s average stock price target has been increased to $15.71 from $15 by 7 analysts, with forecasts ranging from $7 to $27 per share. This new target suggests a potential upside of approximately 198% based on the recent closing price. The consensus rating for ANNX remains a "Buy" from 10 analysts.
Bank of America Corp DE Has $23.60 Million Stock Holdings in Annexon, Inc. $ANNX
Bank of America Corp DE significantly increased its stake in Annexon, Inc. (NASDAQ:ANNX) during the first quarter, now holding 4,259,995 shares valued at $23.60 million. Other institutional investors have also adjusted their positions, and a company director recently acquired over 600,000 shares. Annexon, a clinical-stage biotechnology company focusing on neurodegenerative and neuroimmune diseases, has seen varied analyst ratings, with an average "Hold" rating and a target price of $15.33.
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. (Nasdaq: ANNX) announced inducement grants to three new non-executive employees under the 2022 Employment Inducement Award Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). These employees received options to purchase 287,500 shares of Annexon common stock at an exercise price of $5.29, vesting over four years. This initiative aims to attract and retain talent for the biopharmaceutical company focused on neuroinflammatory diseases.
At $5.29, Annexon grants new employees options vesting over four years
Annexon (Nasdaq: ANNX) announced inducement grants of options to purchase 287,500 shares of common stock to three new non-executive employees. These options, granted at an exercise price of $5.29 per share, vest over four years, with 25% on the first anniversary and the remainder monthly. The grants were made under the 2022 Employment Inducement Award Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
Annexon (NASDAQ:ANNX) Rating Lowered to Strong Sell at Wall Street Zen
Wall Street Zen has downgraded Annexon (NASDAQ:ANNX) from a "sell" to a "strong sell" rating. This decision comes despite some other analysts maintaining "buy" or "hold" ratings for ANNX, with a consensus price target of $15.33. The company recently reported Q2 earnings, missing analyst estimates, and has seen significant insider stock purchases.
Annexon (ANNX) Is Down 6.1% After Dual Endpoint Shift in ARCHER II Trial - What's Changed
Annexon (ANNX) experienced a 6.1% decline in share price following the adoption of a dual primary endpoint in its ARCHER II trial for vonaprument, affecting its investment narrative. Despite a wider Q2 2026 net loss of US$55.35 million, the company secured up to US$200 million in non-dilutive financing, extending its cash runway into 2028. This shift introduces a second assessment point at Month 24 for the trial, potentially broadening regulatory evaluation of the drug's vision-preserving benefits.
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
Annexon, Inc. announced an expansion of its vonaprument Phase 3 ARCHER II trial for geographic atrophy (GA), adding a Month 24 dual primary endpoint to complement the existing Month 15 primary endpoint. This strategy allows for success at either time point and will enable evaluation of the long-term profile of vonaprument. The company also launched an open-label extension study to assess long-term safety and benefits, with Month 15 data expected in Q4 2026 and Month 24 analyses anticipated in Q3 2027.
Insider for ANNX (ANNX) plans sale of 2,000 shares after option exercise
An individual affiliated with Annexon, Inc. (ANNX) has filed a Form 144 notice indicating an intent to sell 2,000 shares of common stock on August 13, 2026. These shares will be acquired through a same-day stock option exercise for cash. The filing also reports prior sales by Thomas Wiggans in July 2026, totaling 3,000 shares for an aggregate of $18,235.00.
A Quick Look at Today's Ratings for Annexon(ANNX.US), With a Forecast Between $8 to $27
This article provides an overview of Annexon (ANNX.US) stock ratings from four analysts in the last quarter, with a consensus price target ranging from $8 to $27. The analysts show a generally bullish sentiment, reflected in their diverse ratings and price targets, indicating varying perspectives on the company's future performance.
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
Annexon, Inc. (Nasdaq: ANNX) has appointed Dr. Mark S. Blumenkranz, a distinguished retinal surgeon and biotechnology entrepreneur, to its board of directors. Dr. Blumenkranz brings over four decades of experience in clinical, scientific, and corporate leadership to Annexon as it advances its late-stage clinical programs. Concurrently, Muneer Satter has stepped down from the board after more than 11 years of service.
Annexon (NASDAQ:ANNX) Upgraded at Citizens Jmp
Citizens JMP upgraded Annexon (NASDAQ:ANNX) from "underperform" to "market perform," while the overall analyst consensus remains a "Hold" with an average price target of $15.33. The company recently reported a quarterly loss of $0.28 per share, missing consensus estimates. Investors are looking ahead to clinical and funding catalysts, including potential 2026 data readouts and regulatory milestones, with current funding expected to last into 2028.
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
Annexon, Inc. has announced an expansion to its Phase 3 ARCHER II trial for vonaprument, a treatment for dry age-related macular degeneration with geographic atrophy. The expansion includes adding a Month 24 dual primary endpoint to complement the existing Month 15 primary endpoint, alongside launching an open-label extension study. This strategy aims to maximize vonaprument's potential to preserve visual acuity and allows for longer-term evaluation of the drug's profile without altering the ongoing study operations.
Annexon shares fall 6% on wider-than-expected quarterly loss
Annexon (NASDAQ:ANNX) reported a second-quarter loss of $0.28 per share, which was wider than the analyst consensus of $0.24 per share, leading to a 6.37% fall in pre-market trading. The biopharmaceutical company attributed the increased loss to higher spending on its late-stage clinical programs, including the Phase 3 ARCHER II trial for geographic atrophy. Despite the wider loss, Annexon highlighted significant clinical progress and secured a $200 million credit facility to extend its financial runway into 2028.
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Annexon, Inc. reported its second-quarter 2026 financial results, highlighting significant progress in its Guillain-Barré syndrome (GBS) and geographic atrophy (GA) programs. The company expects a BLA submission for Tanruprubart in GBS in Q4 2026 and anticipates Month 15 primary endpoint data for Vonaprument in GA in the same quarter, with an expanded dual primary endpoint strategy. Annexon also secured a $200 million credit facility, extending its cash runway into 2028.
Annexon Releases Q2 2026 Financial Results
Annexon, Inc. (ANNX) reported a Q2 2026 basic and diluted loss per share of $0.28, an improvement from $0.34 in the prior year. The clinical-stage biopharmaceutical company posted a net loss of $55.3 million as it continues to invest in its pipeline for inflammatory-related diseases. Wall Street analysts hold a generally positive outlook on the company, with a consensus of 10 buy ratings.
Annexon (NASDAQ:ANNX) Issues Earnings Results, Misses Estimates By $0.05 EPS
Annexon (NASDAQ:ANNX) reported second-quarter earnings, missing analysts' consensus estimates by $0.05 with a loss of $0.28 per share. Despite the earnings miss, the company highlighted positive clinical trial data for tanruprubart in Guillain-Barré syndrome and expanded its ARCHER II geographic atrophy trial. Annexon also secured up to $200 million in non-dilutive financing, extending its cash runway into 2028.
Annexon Q2 Earnings Call Highlights
Annexon (ANNX) announced an expansion of its ARCHER II trial for vonaprument in geographic atrophy, adding a 24-month primary endpoint to capture longer-term efficacy data, alongside the existing 15-month endpoint. The company also provided updates on its Guillain-Barré syndrome (GBS) program, with tanruprubart advancing toward regulatory filings in Europe and the U.S., and reported initial positive results from its FORWARD study. Additionally, Annexon secured a $200 million credit facility, extending its cash runway into 2028.
Earnings call transcript: Annexon misses Q2 2026 EPS view as shares fall premarket
Annexon reported a wider-than-expected Q2 2026 loss of $0.28 per share, leading to a 6.37% premarket stock decline. Despite the earnings miss, the clinical-stage biotech highlighted positive clinical progress for its Guillain-Barré syndrome program, tanruprubart, and expanded the ARCHER II geographic atrophy trial to include a 24-month endpoint to strengthen its long-term profile. The company secured a $200 million credit facility, extending its cash runway into 2028, aiming to translate clinical advancements into new medicines and shareholder value.
Annexon (Nasdaq: ANNX) deepens pipeline, adds $200M credit facility and new endpoints
Annexon (Nasdaq: ANNX) reported its second-quarter 2026 financial results, including a net loss of $55.3 million, but also announced a new $200 million credit facility to extend its cash runway into 2028. The company is advancing its neuroinflammatory pipeline, expanding the Phase 3 ARCHER II trial for vonaprument in geographic atrophy with a dual primary endpoint and anticipating key milestones like a BLA submission for tanruprubart and proof-of-concept data for ANX1502 in late 2026 and 2027. Despite ongoing losses, Annexon highlights strengthened liquidity and progress in its clinical programs for Guillain-Barré syndrome and geographic atrophy.
Tanruprubart Shows Rapid Responses in First FORWARD Cohort for Guillain-Barre Syndrome
Annexon reported rapid, clinically meaningful improvements in strength among all 10 patients in the first US and European cohort of its open-label FORWARD study for Guillain-Barré syndrome (GBS) following a single tanruprubart infusion. These results, including ambulation for bedbound patients and ventilator liberation, are consistent with prior phase 3 and real-world evidence. Tanruprubart, which targets C1q to inhibit neuroinflammation, is currently under EMA review, and FORWARD data will support a planned FDA BLA submission in Q4 2026.
Form 8K Annexon Inc For: 10 August By Investing.com
This article announces the filing of Form 8K by Annexon Inc. on August 10. The content itself is very brief, serving primarily as a notification of the regulatory filing and is published by Investing.com. It also includes various market data, news headlines, and stock performance figures from Investing.com.
Annexon names Mark Blumenkranz to board as Muneer Satter steps down
Annexon has appointed retinal surgeon and biotech entrepreneur Mark S. Blumenkranz to its board of directors. Blumenkranz, a Stanford ophthalmology professor emeritus and co-director of its Ophthalmic Innovation Program, has extensive experience in the ophthalmic industry, having co-founded Adverum Biotechnologies and led several companies through acquisitions. Concurrently, director Muneer Satter has stepped down from the board.
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
Annexon, Inc. has appointed Dr. Mark S. Blumenkranz, a distinguished retinal surgeon and biotechnology entrepreneur, to its board of directors. Dr. Blumenkranz brings extensive experience in advancing therapies for retinal diseases, aligning with Annexon's focus on neuroinflammatory diseases. Concurrently, Muneer Satter will step down from the board after 11 years of service.
Form 8K Annexon Inc For: 10 August By Investing.com
This article announces that Annexon Inc. filed a Form 8K on August 10th. The filing is brief and does not contain additional details beyond the date of the filing and the company involved.
Annexon appoints retinal surgeon Blumenkranz to board By Investing.com
Annexon, Inc. (NASDAQ:ANNX) has appointed retinal surgeon Mark S. Blumenkranz, M.D., M.M.S., to its board of directors. Concurrently, Muneer Satter will step down from the board after more than 11 years of service. Blumenkranz brings extensive experience from Stanford University and has co-founded several ophthalmic and life sciences companies.
Annexon names Mark Blumenkranz to board as Muneer Satter steps down
Annexon has appointed retinal surgeon and biotech entrepreneur Mark S. Blumenkranz to its board of directors. Blumenkranz, a Stanford ophthalmology professor emeritus and co-director of its Ophthalmic Innovation Program, has a strong background in founding and leading ophthalmic companies. This appointment follows the stepping down of director Muneer Satter from the board.
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
Annexon, Inc. (Nasdaq: ANNX) has appointed Dr. Mark S. Blumenkranz, a distinguished retinal surgeon and biotechnology entrepreneur, to its board of directors. Dr. Blumenkranz brings over four decades of experience in retinal disease innovation, which will be crucial as Annexon advances its late-stage clinical programs. Concurrently, Muneer Satter has stepped down from the board after more than 11 years of service.
Renaissance Technologies LLC Sells 258,300 Shares of Annexon, Inc. $ANNX
Renaissance Technologies LLC reduced its stake in Annexon, Inc. (NASDAQ:ANNX) by 32.2%, selling 258,300 shares but still retaining 544,300 shares valued at approximately $3.0 million. While Renaissance Technologies reduced its holdings, other institutional investors like AQR Capital Management and Acadian Asset Management increased their positions. Notably, Annexon insiders, including Director William Carson and Director Muneer Satter, also made significant purchases, with insiders collectively owning 10.31% of the company.
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
Annexon, Inc. announced early positive results from the first ten U.S. and European patients in its open-label FORWARD study for Guillain-Barré syndrome (GBS) treated with tanruprubart. The study demonstrated rapid, clinically meaningful improvements in strength and reduced disability within days of a single infusion, consistent with previous Phase 3 and Real-World Evidence findings. This drug has the potential to be the first approved targeted therapy for GBS worldwide, addressing a significant unmet need and high healthcare burden.
Annexon Inc (ANNX) Stock News Today
This article provides an update on Annexon Inc (ANNX) stock news, earnings, analyst ratings, and key developments. It notes that more news is expected soon and invites users to stay tuned. The article also presents current stock performance data for ANNX.
Wells Fargo Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $27
Wells Fargo has reaffirmed its Buy rating on Annexon (ANNX.US), holding its target price at $27. This continued endorsement suggests the firm's confidence in Annexon's future performance.
State Street Corporation (ANNX) discloses 9.8M-share, 6% holding in Annexon
State Street Corporation has disclosed a 6% holding in Annexon Inc. (ANNX), amounting to 9,824,321 common shares, as per a Schedule 13G filing. The shares are held for passive investment purposes with shared voting power over 9,572,419 shares and shared dispositive power over all 9,824,321 shares. This stake is managed through various State Street Global Advisors investment management subsidiaries.
Goldman Sachs reiterates Neutral on Annexon stock after GBS data
Goldman Sachs has reiterated a Neutral rating and $7.00 price target on Annexon Biosciences (NASDAQ: ANNX) following the release of initial data from its FORWARD study for Guillain-Barré syndrome (GBS). The study showed rapid and meaningful improvement in patients, supporting a planned biologics license application. The firm estimates peak sales of approximately $850 million for the treatment, tanruprubart, while awaiting more detailed data and the Phase 3 ARCHER II data for vonaprument.
Annexon, Inc. Reports Early Clinical Responses in First U.S. and European Patient Cohort of GBS FORWARD Study with Tanruprubart
Annexon, Inc. announced early positive results from the first ten U.S. and European patients in its GBS FORWARD study of tanruprubart. The study showed rapid and clinically meaningful improvements in strength and reduced disability within days for patients with Guillain-Barré syndrome (GBS), a life-threatening neuroinflammatory disease. These outcomes are consistent with Phase 3 results and will support Annexon's planned Biologics License Application (BLA) submission in Q4 2026.
